Omar Oliveros
Internal Medicine · Chicago, ILNPI 1538542337
Payments from drug & device makers
Across 385 payments — averaging $28.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$2K
- Boehringer Ingelheim$1K
- Amgen$1K
- AbbVie$557
- Lilly USA, LLC$545
- plus $3K from 18 others
What the payments were for
- Food & beverage$10,852100%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $2,555 |
| Novo Nordisk | 56 | $1,524 |
| Boehringer Ingelheim | 52 | $1,230 |
| Amgen | 28 | $1,095 |
| AbbVie | 34 | $557 |
| Lilly USA, LLC | 25 | $545 |
| Bayer | 16 | $520 |
| Corcept Therapeutics | 15 | $417 |
| GSK | 14 | $385 |
| Redhill Biopharma Inc. | 27 | $307 |
| Merck | 18 | $287 |
| Esperion Therapeutics, Inc. | 2 | $268 |
| Pfizer | 5 | $192 |
| Phadia US Inc. | 1 | $192 |
| Novartis | 8 | $163 |
| Johnson & Johnson | 3 | $139 |
| Aimmune Therapeutics, Inc. | 1 | $124 |
| Exact Sciences | 5 | $119 |
| E.r. Squibb & Sons, L.L.C. | 6 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Hologic Sales And Service, LLC | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,883 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 104 | $156,746 |
| FarxigaDapagliflozin Propanediol | 99 | $122,577 |
| RybelsusSemaglutide | 50 | $105,157 |
| OzempicSemaglutide | 34 | $57,037 |
| KerendiaFinerenone | 34 | $53,611 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $47,614 |
| LinzessLinaclotide | 37 | $44,753 |
| CreonLipase/Protease/Amylase | 11 | $42,372 |
| TrulicityDulaglutide | 26 | $42,136 |
| VascepaIcosapent Ethyl | 25 | $26,418 |
| EntrestoSacubitril/Valsartan | 20 | $26,315 |
| MyrbetriqMirabegron | 22 | $23,553 |
| MounjaroTirzepatide | 21 | $22,593 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $12,758 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $12,220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,524 | $162,19484 claims |
| Boehringer IngelheimJardiance | $1,230 | $156,746104 claims |
| AstraZenecaFarxiga | $2,555 | $122,57799 claims |
| AbbVieLinzess, Creon | $557 | $87,12548 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $545 | $64,72847 claims |
| GSKTrelegy Ellipta, Shingrix | $385 | $55,69666 claims |
| BayerKerendia | $520 | $53,61134 claims |
| NovartisEntresto | $163 | $26,31520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Dennis LevinsonChicago$25.3M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Mohammed KassemChicago$1.3M
- David BakerChicago$1M
- Azazuddin AhmedChicago$912K
- Daniel BergerChicago$861K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.